Osiris Therapeutics reported that its Grafix wound-care product, which releases stem cells straight to the wound site to allow tissue regeneration, demonstrated effectiveness in treating patients with diabetic foot ulcers in a postmarket study. The study found that complete wound closure was achieved in 62% of patients who were treated with Grafix, compared with 21% of those who received traditional therapy.
Wound-care product from Osiris shows positive trial results
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan